Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

A Comparative Bioavailability Study of Lomitapide 20 mg Intact vs Sprinkled

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02044419
Recruitment Status : Completed
First Posted : January 24, 2014
Results First Posted : February 13, 2018
Last Update Posted : February 13, 2018
Sponsor:
Information provided by (Responsible Party):
Aegerion Pharmaceuticals, Inc.

Brief Summary:
To compare the relative bioavailability of lomitapide when administered by sprinkling the contents of a 20 mg capsule of lomitapide in applesauce or in mashed banana to a single oral intact capsule dose of 20 mg lomitapide in healthy subjects.

Condition or disease Intervention/treatment Phase
Healthy Drug: lomitapide Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Phase 1, Open-label, Randomised, Crossover Study to Determine the Comparative Bioavailability of 20 mg Lomitapide Where the Contents Have Been Opened and Sprinkled in Applesauce or Mashed Banana ("Sprinkled Contents") to a Single Oral Capsule Dose of 20 mg Lomitapide ("Intact Capsule") in Healthy Subjects
Actual Study Start Date : October 30, 2013
Actual Primary Completion Date : December 23, 2013
Actual Study Completion Date : December 23, 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Lomitapide

Arm Intervention/treatment
Experimental: lomitapide sprinkled in applesauce
Contents of single 20 mg capsule of lomitapide sprinkled in applesauce
Drug: lomitapide
Other Names:
  • Juxtapid
  • Lojuxta

Experimental: lomitapide sprinkled in mashed banana
Contents of single 20 mg capsule of lomitapide sprinkled in mashed banana
Drug: lomitapide
Other Names:
  • Juxtapid
  • Lojuxta

Experimental: lomitapide (intact)
Intact capsule of 20 mg lomitapide
Drug: lomitapide
Other Names:
  • Juxtapid
  • Lojuxta




Primary Outcome Measures :
  1. AUC0-t [ Time Frame: predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose ]
    Area under the concentration-time curve from hour 0 to the last measurable concentration of lomitapide and its metabolites (M1& M3).

  2. Cmax [ Time Frame: predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose ]
    Maximum observed concentration of lomitapide and its metabolites (M1& M3).

  3. Tmax [ Time Frame: predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose ]
    Time to reach maximum plasma concentration of lomitapide and its metabolites (M1& M3).

  4. t1/2 [ Time Frame: predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose ]
    Terminal elimination half-life of lomitapide and its metabolites (M1& M3).

  5. AUC0-∞ [ Time Frame: predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose ]
    Area under the plasma concentration vs time curve from zero to infinity of lomitapide and its metabolites (M1& M3).

  6. λz [ Time Frame: predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose ]
    Elimination rate constant estimated from individual linear regression of the terminal part of the log concentration vs time curve of lomitapide and its metabolites (M1& M3).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subject is a non-smoking healthy male or female, aged between 18 and 40 years of age.
  2. Subject has a BMI of 18.5 - 25 kg/m2.
  3. Subject has total body weight between > 50 kg to ≤ 100 kg.
  4. Subjects must agree to use acceptable methods of contraception.
  5. All females, regardless of childbearing potential, must have a negative serum beta human chorionic gonadotropin pregnancy test at Screening and on admission.
  6. In good health, determined by no clinically significant or relevant abnormalities identified by a detailed medical history & full physical examination.
  7. No known history of hypersensitivity or previous intolerance to lomitapide, applesauce, and/or banana.
  8. Subjects must be capable of understanding and complying with the requirements of the protocol and must have signed the informed consent form prior to undergoing any study-related procedures.

Exclusion Criteria:

  1. Subject has a clinically significant disease or any condition or disease that might affect drug absorption, distribution or excretion.
  2. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs.
  3. Any clinically significant abnormal laboratory, vital signs or other safety findings as determined by medical history, physical examination or other evaluations.
  4. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator;
  5. Electrocardiogram (ECG) abnormalities in the standard 12-lead ECG (at screening) such as a QTcF interval of >450 msec, a history of a prolonged QTc interval or Brugada syndrome.
  6. History or current evidence of any clinically relevant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrinological, allergic, dermatological, metabolic, neurological, psychiatric or other disease.
  7. History or laboratory evidence of Gilbert's syndrome.
  8. Positive results in any of the serology tests for Hepatitis B Surface Antigen (HbsAg), anti-Hepatitis core antibody (anti-HBc Ig G [and anti-HBc IgM if IgG is positive], Hepatitis C antibodies (anti-HCV), and HIV 1 and 2 antibodies, (anti-HIV 1/2).
  9. Use of any drugs of abuse within 6 months prior to admission.
  10. Confirmed positive results from urine drug screen (amphetamines, benzodiazepines, cocaine, cannabinoids, opiates, barbiturates and methadone) or from the alcohol breath test at screening and on admission (Day -1).
  11. History or clinical evidence of alcohol or drug abuse within one year prior to admission.
  12. Mentally handicapped.
  13. Participation in a drug trial within 90 days prior to first drug administration.
  14. Use of any prescription medication within 2 weeks prior to admission (Day -1), with the exception of the oral contraceptive pill.
  15. Use of any substance inducing or inhibiting CYP3A4 enzymes within 30 days prior to admission (Day -1).
  16. Use of any over-the-counter (OTC) medication (including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) within 7 days prior to admission (Day -1), unless deemed acceptable by the Investigator and Sponsor.
  17. Use of alcohol-, grapefruit-, starfruit-, or caffeine-containing foods or beverages within 72 hours prior to admission and through Study Completion.
  18. Donation of more than 500 mL of blood within 90 days prior to drug administration.
  19. Receipt of blood products within 2 months prior to admission.
  20. Poor peripheral venous access.
  21. Use of any tobacco- or nicotine-containing products within 6 months prior to admission (Day -1).
  22. Any acute or chronic condition, scheduled hospitalisation (inclusive of elective surgery during study), or scheduled travel prior to completion of all study procedures.
  23. Any circumstances or conditions, which, in the opinion of the PI, may affect full participation in the trial or compliance with the protocol.
  24. Legal incapacity or limited legal capacity at screening.
  25. Subjects who are vegetarians, vegans or have any dietary restrictions conflicting with the study standardised menus.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02044419


Locations
Layout table for location information
United Kingdom
Richmond Pharmacology Ltd
Croydon, Surrey, United Kingdom, CR7 7YE
Sponsors and Collaborators
Aegerion Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Study Chair: Mark Sumeray, MD Aegerion Pharmaceuticals, Inc.
Principal Investigator: Ulrike Lorch, MD Richmond Phamacology, LTD

Layout table for additonal information
Responsible Party: Aegerion Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT02044419    
Other Study ID Numbers: AEGR-733-032
First Posted: January 24, 2014    Key Record Dates
Results First Posted: February 13, 2018
Last Update Posted: February 13, 2018
Last Verified: February 2018
Keywords provided by Aegerion Pharmaceuticals, Inc.:
Comparative
Bioavailability
lomitapide